Abstract
Background: Cilostazol is frequently used to treat and prevent thrombosis in Korean patients. Patients and methods: We performed the pharmacokinetic and correlation analysis of cilostazol in Korean healthy subjects. A total of male 78 volunteers was subjected to three separate bioequivalence studies in which 100 mg of cilostazol was administered. AUC, t 1/2, and C max were 12,100 ± 4,880 ngxh/ml, 11.1 ± 4.4 hours, and 827 ± 361 ng/ml, respectively. Results: ALT was positively correlated with age and C max was positively correlated with AUC, but negatively correlated with body weight. Conclusion: We suggest that the unique pharmacokinetic parameters and interrelationship can help to understand the pharmacokinetics of cilostazol in Korean subjects.
| Original language | English |
|---|---|
| Pages (from-to) | 345-348 |
| Number of pages | 4 |
| Journal | International Journal of Clinical Pharmacology and Therapeutics |
| Volume | 50 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2012 May 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmacology (medical)
Cite this
}
Pharmacokinetics and correlation analysis of cilostazol in healthy Korean subjects. / Choi, Hye Duck; Lee, Hye Jung; Lee, Sang Hun; Kim, Soo Hwan; Choi, Chung Am; Chang, Min Jung; Shin, Wan Gyoon.
In: International Journal of Clinical Pharmacology and Therapeutics, Vol. 50, No. 5, 01.05.2012, p. 345-348.Research output: Contribution to journal › Article
TY - JOUR
T1 - Pharmacokinetics and correlation analysis of cilostazol in healthy Korean subjects
AU - Choi, Hye Duck
AU - Lee, Hye Jung
AU - Lee, Sang Hun
AU - Kim, Soo Hwan
AU - Choi, Chung Am
AU - Chang, Min Jung
AU - Shin, Wan Gyoon
PY - 2012/5/1
Y1 - 2012/5/1
N2 - Background: Cilostazol is frequently used to treat and prevent thrombosis in Korean patients. Patients and methods: We performed the pharmacokinetic and correlation analysis of cilostazol in Korean healthy subjects. A total of male 78 volunteers was subjected to three separate bioequivalence studies in which 100 mg of cilostazol was administered. AUC, t 1/2, and C max were 12,100 ± 4,880 ngxh/ml, 11.1 ± 4.4 hours, and 827 ± 361 ng/ml, respectively. Results: ALT was positively correlated with age and C max was positively correlated with AUC, but negatively correlated with body weight. Conclusion: We suggest that the unique pharmacokinetic parameters and interrelationship can help to understand the pharmacokinetics of cilostazol in Korean subjects.
AB - Background: Cilostazol is frequently used to treat and prevent thrombosis in Korean patients. Patients and methods: We performed the pharmacokinetic and correlation analysis of cilostazol in Korean healthy subjects. A total of male 78 volunteers was subjected to three separate bioequivalence studies in which 100 mg of cilostazol was administered. AUC, t 1/2, and C max were 12,100 ± 4,880 ngxh/ml, 11.1 ± 4.4 hours, and 827 ± 361 ng/ml, respectively. Results: ALT was positively correlated with age and C max was positively correlated with AUC, but negatively correlated with body weight. Conclusion: We suggest that the unique pharmacokinetic parameters and interrelationship can help to understand the pharmacokinetics of cilostazol in Korean subjects.
UR - http://www.scopus.com/inward/record.url?scp=84860760003&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860760003&partnerID=8YFLogxK
U2 - 10.5414/CP201671
DO - 10.5414/CP201671
M3 - Article
C2 - 22541839
AN - SCOPUS:84860760003
VL - 50
SP - 345
EP - 348
JO - International Journal of Clinical Pharmacology and Therapeutics
JF - International Journal of Clinical Pharmacology and Therapeutics
SN - 0946-1965
IS - 5
ER -